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Abstract
Background: An increase in the use of drugs and polypharmacy have been displayed over time in spite of the
fact that polypharmacy represents a well known risk factor as regards patients’ health due to the adverse drug
reactions, drug-drug interactions, and low adherence to drug therapy arising from polypharmacy. For policymakers,
as well as for clinicians, it is important to follow the developing trends in drug use and polypharmacy over time.
We wanted to study if the prevalence of polypharmacy in an entire national population has changed during a
4-year period.
Methods: By applying individual-based data on dispensed drugs, we have studied all dispensed prescribed drugs
for the entire Swedish population during four 3-month periods 2005-2008. Five or more (DP ≥5) and ten or more
(DP ≥10) dispensed drugs during the 3-month period was applied as the cut-offs indicating the existence of
polypharmacy and excessive polypharmacy respectively.
Results: During the period 2005-2008, the prevalence of polypharmacy (DP≥5) increased by 8.2% (from 0.102 to
0.111), and the prevalence of excessive polypharmacy (DP≥10) increased by 15.7% (from 0.021 to 0.024).
In terms of age groups, the prevalence of polypharmacy and excessive polypharmacy increased as regards all ages
with the exception of the age group 0-9 years. However, the prevalence of excessive polypharmacy displayed a
clear age trend, with the largest increase for the groups 70 years and above. Furthermore, the increase in the pre-
valence of polypharmacy was, generally, approximately twice as high for men as for women. Finally, the mean
number of dispensed drugs per individual increased by 3.6% (from 3.3 to 3.4) during the study period.
Conclusions: The prevalence of polypharmacy and excessive polypharmacy, as well as the mean number of
dispensed drugs per individual, increased year-by-year in Sweden 2005-2008.
Background
It is clear that a continuous increase in the overall level
of drug use, especially among elderly, has been noted in
several countries. Moreover, an increase in the number
of individuals experiencing polypharmacy, ie. the con-
current use of several different drugs, has also been
reported [1-3].
Whilst the use of a number of different drugs for
many individuals appears to be a rational drug therapy,
and polypharmacy is assumed to provide major health
benefits for the well being of large groups of individuals
suffering from different diseases, polypharmacy is also a
well known risk factor due to adverse drug reactions,
drug-drug interactions, and low adherence to drug ther-
apy [3-5].
In addition, it is also assumed that polypharmacy
causes unnecessary health expenditure [5], directly due
to redundant drug sales and indirectly due to the
increased level of hospitalization caused by drug-related
problems [6]. Drug-related problems are reported to
cause a substantial proportion of all emergency treat-
ment and admissions to hospitals as regards elderly
patients [4,7]. Consequently, there have been many
attempts to reduce the number of prescribed drugs to
individuals experiencing polypharmacy, especially as
regards the elderly [1].
Furthermore, it should also be noted that previous
studies of polypharmacy have primarily been conducted
on samples of elderly individuals admitted to hospitals
or nursing homes [5,8]. Only a few studies have been
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some of these studies have also been limited to elderly
individuals [11-14]. A recent register study showed that
2/3 of all individuals in a national population who were
being prescribed with 5 or more drugs were < 70 years
of age [15], indicating that multiple medication use is
not only relevant as regards elderly individuals.
Clearly, for policymakers, as well as for clinicians, it is
important to follow the developing trends in drug use
and polypharmacy over time, and not only in the elderly
age groups but also for the large number of middle-aged
individuals subject to polypharmacy. In this context, the
establishment of the Swedish Prescribed Drug Register
i n2 0 0 5m a d ei tp o s s i b l et oa p p l yi n d i v i d u a ld a t ai n
exploring and analyzing the utilization of polypharmacy
in an entire national population. Such individual-based
data may also be applied in longitudinal studies of the
development of drug use.
Aim of the study
We wanted to study if the prevalence of polypharmacy
in an entire national population has changed during a
4-year period.
Methods
By using individual based data on dispensed drugs, we stu-
died all dispensed prescribed drugs for the entire Swedish
population during four 3-month periods (July, August and
September) 2005-2008. These data were extracted from
the Swedish Prescribed Drug Register [10].
In this study, the prevalence of polypharmacy was
defined as the proportion of individuals receiving five or
more dispensed prescription drugs (DP≥5) during a
3-month period.
As a definition of excessive polypharmacy, we applied
ten or more dispensed drugs (DP≥10) for an individual
during the study period [12]. Consequently, the preva-
lence of excessive polypharmacy was defined as the pro-
portion of individuals receiving ten or more dispensed
drugs during a 3-month period. As five or more dis-
pensed drugs comprises the most commonly applied
definition of polypharmacy [8,12,16] and 10 or more
dispensed drugs is the most widely used definition of
“excessive” polypharmacy [9,12,16,17] our definitions are
intended to enable comparisons with other studies.
The development of the prevalence of drug use
defined as the proportion of individuals with one or
more dispensed drugs (DP≥1) during a 3-month period
is illustrated for purpose of comparison.
The Swedish Prescribed Drug Register
The Swedish Prescribed Drug Register covers the entire
Swedish population and includes approximately 82% of
all Defined Daily Doses (DDD) dispensed in Sweden.
The register does not include data on OTC medications
(13%), in-hospital medications (4%), and non-institu-
tional care medications (1% of all DDD distributed in
Sweden). This register is not complete as regards vac-
cines or for non-dose-dispensed drugs in nursing
homes.
The Swedish Prescribed Drug Register is individual-
based and contains data from dispensed out-patient pre-
scriptions at all Swedish pharmacies from July 1, 2005.
The registration of dispensed drugs is mandatory and
the following data from the register was used in our
study: dispensed drug (substance), date of dispensing,
age, gender, and a unique identifier (personal identifica-
tion number) of the patient.
All processing of the individual data of dispensed drugs
in our study was undertaken anonymously, without the
original personal identification number. Instead, a unique
temporary individual identifier, specifying gender and
year of birth, was applied and the study population was
stratified by gender and age (10-year classes). The results
of our study were presented with respect to the number
of individuals per gender and age group in the Swedish
population during the corresponding periods.
Also, the values applied were the number of indivi-
duals and the number of dispensed prescription drugs
per individual, and the definition of drug was the chemi-
cal entity or substance comprising the fifth level in the
Anatomical Therapeutic Chemical (ATC) classification
system.
Calculation of sums and frequencies were aggregated
using Microsoft Excel (version 5.1.26).
The study was approved by the Regional Ethical
Review Board in Linköping, Sweden.
Results
The development of polypharmacy
T h ep r e v a l e n c eo fp o l y p h a r m a c y( D P ≥5) in the entire
population increased by 8.2% (from 0.102 to 0.111)
2005-2008 (Table 1). The number of individuals with
DP≥5 increased by 10.4% (from 922,949 to 1,019,324)
(Table 2).
The prevalence increased in all age groups, except for
the age group 0-9 years and the largest increase in the
prevalence was in the age group 10-19 with an increase
of 9.1%. In the age groups 60-69 to 90-years, the
increase was between 7.2% and 8.6% (Figure 1).
For men, the prevalence of polypharmacy (DP≥5)
increased in all age groups (11.9%) except for the age
group 0-9 years. The largest increase in the prevalence of
polypharmacy was in the age group 60-69 with an increase
of 12.3%, whilst in the age groups 70-79 to 90-years, the
increase was between 8.4% and 10.1% (Figure 2).
For women, the prevalence of polypharmacy (DP≥5)
increased in all age groups (5.9%) except for the age
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was in the age group 10-19 with an increase of 13.3%,
whilst in the age groups 60-69 to 90-years, the increase
was between 5.8% and 7.6% (Figure 2).
The development of excessive polypharmacy
The prevalence of excessive polypharmacy (DP≥10) in
the entire population increased by 15.7% (from 0.021 to
0.024) 2005-2008 (Table 1). The number of individuals
with DP≥10 increased by 18.1% (from 185,618 to
219,244) (Table 2).
The level of prevalence increased in all age groups
except for the age group 0-9 years and the largest
increase in the prevalence was in the age group 90-with
an increase of 28.5%. In the age groups 60-69 to 80-89
years, the increase was between 10.6% and 21.6%
(Figure 1).
For men, the prevalence of excessive polypharmacy
(DP≥10) increased in all age groups (20.2%), except for
the age group 0-9 years. The largest increase in the
prevalence was in the age group 90-, with an increase of
36.4%. In the age groups 60-69 to 80-89 years, the
increase was between 15.7% and 23.0% (Figure 3).
For women, the prevalence of excessive polypharmacy
(DP≥10) increased all age groups (13.5%), except for the
age group 0-9 years. The largest increase in the preva-
lence was in the age group 90-with an increase of
26.8%, and in the age groups 60-69 to 90-years, the
increase was between 7.3% and 21.2% (Figure 3).
The development of the mean number of dispensed
drugs per individual
The mean number of dispensed drugs per individual,
during a 3-month period for all individuals in Sweden
receiving dispensed drugs, increased by 3.6% (from 3.3
to 3.4 drug per individual) during the study period
2005-2008.
For elderly individuals, 70 years and above, the mean
number of dispensed drugs per individual increased by
3.9% (from 4.8 to 5.0 drugs), by 6.1% (from 5.7 to 6.1
Table 1 The prevalence of dispensed drugs, polypharmacy, and excessive polypharmacy
Age group DP≥1D P ≥5D P ≥10
2005 2006 2007 2008 2005 2006 2007 2008 2005 2006 2007 2008
0-9 0.183 0.194 0.184 0.188 0.005 0.005 0.005 0.005 0.000 0.000 0.000 0.000
10-19 0.214 0.223 0.228 0.238 0.008 0.008 0.008 0.008 0.000 0.000 0.000 0.001
20-29 0.314 0.313 0.308 0.304 0.016 0.017 0.017 0.017 0.001 0.001 0.001 0.001
30-39 0.332 0.337 0.335 0.333 0.029 0.029 0.029 0.030 0.003 0.003 0.003 0.004
40-49 0.390 0.396 0.395 0.394 0.053 0.054 0.055 0.056 0.008 0.008 0.009 0.009
50-59 0.533 0.536 0.537 0.536 0.113 0.115 0.117 0.119 0.019 0.020 0.020 0.021
60-69 0.640 0.649 0.657 0.662 0.197 0.202 0.209 0.214 0.037 0.039 0.040 0.041
70-79 0.784 0.789 0.794 0.797 0.350 0.359 0.367 0.376 0.078 0.083 0.085 0.088
80-89 0.833 0.843 0.849 0.853 0.475 0.492 0.504 0.514 0.121 0.139 0.143 0.147
90- 0.780 0.790 0.790 0.795 0.494 0.524 0.524 0.532 0.126 0.159 0.160 0.162
Total 0.426 0.433 0.433 0.436 0.102 0.105 0.108 0.111 0.021 0.022 0.023 0.024
The prevalence of dispensed drugs (DP≥1), polypharmacy (DP≥5), and excessive polypharmacy (DP≥10) in different age groups in Sweden 2005-2008.
n = 9,029,750 (2005), 9,080,505 (2006) 9,148,092 (2007) and 9,219,637 (2008).
Table 2 Number of individuals with polypharmacy, and excessive polypharmacy
Age group DP≥5D P ≥10
2005 2006 2007 2008 2005 2006 2007 2008
0-9 4,698 4,829 4,529 4,653 243 235 246 230
10-19 9,082 8,974 9,300 9,693 579 578 574 620
20-29 17,598 17,993 18,481 18,930 1,486 1,598 1,601 1,646
30-39 35,926 36,118 35,857 36,297 4,129 4,312 4,230 4,345
40-49 64,044 66,952 69,170 70,883 9,666 10,058 10,730 10,919
50-59 137,191 137,651 138,873 139,519 22,785 23,587 23,763 24,142
60-69 191,510 205,066 220,723 234,603 36,053 39,159 42,206 44,942
70-79 231,413 236,654 242,252 250,348 51,575 54,790 56,488 58,788
80-89 195,172 203,814 208,939 213,207 49,833 57,490 59,282 61,060
90- 36,315 39,228 39,985 41,191 9,269 11,884 12,197 12,552
Total 922,949 957,279 988,109 1,019,324 185,618 203,691 211,317 219,244
Number of individuals with polypharmacy (DP≥5), and excessive polypharmacy (DP≥10) in different age groups in Sweden 2005-2008.
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Figure 1 The change in prevalence of dispensed drugs, polypharmacy, and excessive polypharmacy. The change (%) in prevalence of
dispensed drugs (DP≥1), polypharmacy (DP≥5), and excessive polypharmacy (DP≥10) in different age groups in Sweden during 2005-2008.
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Figure 2 The change in prevalence of polypharmacy for men and women. The change (%) in prevalence of polypharmacy (DP≥5) for men
and women in different age groups in Sweden 2005-2008.
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respective age groups. The increase (%) of the mean
number of dispensed drugs for men and for women was
similar.
Discussion
Principal findings and possible explanations
The prevalence of polypharmacy and excessive poly-
pharmacy increased year-by-year, in the entire Swedish
population 2005-2008.
With the exception of the age group 0-9 years, the
prevalence of polypharmacy and excessive polypharmacy
increased in all age groups. The prevalence of excessive
polypharmacy displayed a clear age trend, with the lar-
gest increase for the age groups 70 years and above.
Generally, the increase in the prevalence of polyphar-
macy was approximately twice as high for men as for
women, and the increase in prevalence of excessive
polypharmacy was about 1.5 as high for men as for
women.
The increase rate for both polypharmacy and excessive
polypharmacy levelled out during the study period, but
between separate years, we noted a variation in rate of
increase. This variation refers to the different age groups
and to both genders.
The increase in the prevalence of polypharmacy may
have several different causes: changes in the recom-
mended prescriptions for various drug treatments as
well as the introduction of specific drugs for treatment
of conditions/diseases regarding which they have pre-
viously not been applied. Furthermore, middle-aged
individuals are increasingly informed, and become, con-
sequently, more prone to request an increased amount
of prescription drugs. Finally, more drugs are being pre-
scribed for preventive use. All together, these factors
may have resulted in a change in the physicians’ pre-
scription patterns.
The decrease in the prevalence of polypharmacy in the
age group 0-9 years can be explained by the national
interventions to reduce the prescribing of antibiotics to
children, in order to prevent antimicrobial resistance.
Nearly 80% of the children 0-9 years with polypharmacy
received antibiotics in 2006, clearly indicating that anti-
biotics have the largest impact on the prevalence of
polypharmacy in this particular age group [15].
Both the overall increase and the differences in the
rate of increase between the years are puzzling. These
increases suggest relatively rapid changes in prescription
patterns among prescribers; changes that may have a
variety of causes, e.g. the introduction of new clinical
guidelines.
Prior to 2005, national clinical guidelines were avail-
able for only three different areas in Sweden. During the
study period, 2005-2008, The National Board of Health
and Welfare in Sweden introduced four new national
clinical guidelines; Stroke, Chest-Colorectal cancer and
Prostate cancer, Heart disease, and Addiction, and in
2009-2011 seven other new clinical guidelines are
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Figure 3 The change in prevalence of excessive polypharmacy for men and women. The change (%) in prevalence of excessive
polypharmacy (DP≥10) for men and women in different age groups in Sweden 2005-2008.
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Diabetics, Lung cancer).
Prior to being officially introduced, new clinical guide-
lines exist only in preliminary versions. Consequently,
these guidelines might influence the prescription habits
and the development of polypharmacy a number of
years before the guidelines being officially introduced.
The introduction of national clinical guidelines for heart
diseases and prostate cancer might explain both the
unequal increase between genders, and the variation in
increase rate between the different years.
In a study from Sweden concerning general practi-
tioners’ (GPs’) perceptions of multiple-medicine use
[18], clinical guidelines were viewed as “medicine gen-
erators”. GPs’ expressed frustration concerning guideline
recommendations for certain diagnoses, e.g. cardiovas-
cular diagnoses that “immediately result in five medi-
cines”. Regardless of the patients’ other diseases, many
guidelines were perceived as too rigid, leading to a stan-
dard “kit” of medicines per indication, and thereby
resulting in that individuals with multiple diseases
received an increasing number of different drugs.
The introduction of new national guidelines might
therefore also contribute to explaining the age trend in
the development of excessive polypharmacy, as older
patients are more often exposed to several diseases. The
elderly may receive, as a result of the guidelines, more
o f t e nt h a no t h e r s ,an u m b e ro fd i f f e r e n t“kits” of drugs
added [18].
Strengths and weaknesses of the study
Our study presents an overview of the development of
polypharmacy in an entire national population. The
applied 3-month period prevalence of dispensed drugs
includes all drugs that are prescribed on a regular basis
(e.g. drug used in diabetes), when needed (e.g. analge-
sics), and temporarily (e.g. antibiotics). The periodically
used drugs have been shown to have a different impact
o nt h ep r e v a l e n c eo fp o l y p h a r m a c yi nd i f f e r e n ta g e
groups [15].
As the study included all individuals in the population,
we avoided certain known problems concerning sam-
pling, recall, interview and confidence. On the other
hand, when the register data regarding the dispensed
drugs is used as an estimator of drug use and polyphar-
macy, over-as well as underestimations of actual drug
use arises. The extracted data included dispensed pre-
scription drugs only, corresponding to approximately
82% of all Defined Daily Doses (DDD) distributed in
Sweden. Also, additional sources of drugs, such as OTC
medications, in-hospital medications and non-institu-
tional care medications, herbal and alternative remedies
together with previously filled prescriptions (before the
study period), gifts and elicit Internet sales, were not
included in the study, and resulted in an underestima-
tion of the total consumption of drugs.
In addition, generic duplication (intended and unin-
tended duplication of dispensed drugs with the same
substance) might also have caused an underestimation
of polypharmacy in our data, as we calculated only the
number of dispensed drugs comprised of different sub-
stances. In sample studies of drug use among indivi-
duals with polypharmacy, patients often have two or
more drugs with the same substance [4,19,20]. In regis-
ter studies, it is difficult to make distinction between
generic duplication and generic substitution (an
intended switch between two drugs with the same sub-
stance). If the generic duplicate had been taken into
account, this would have resulted in an even larger pre-
valence of polypharmacy. Whether the generic duplicate
could have any impact on the development of the pre-
valence of polypharmacy over the study period has not
been addressed.
Conversely, dispensed drugs as an indicator of drug
use might result in an overestimation, as it is well
k n o w nt h a tac e r t a i np r o p o r t i o no fa l ld i s p e n s e dd r u g s
will never be used [21].
Strengths and weaknesses in relation to other studies
The displayed increase of polypharmacy in the entire
population in Sweden since 2005 is in line with studies
focusing only on elderly individuals during the 1980’s
and 1990’s [2,22-25].
However, there are certain difficulties in comparing
our results concerning the elderly population with some
of the previous studies. Firstly, some studies have
addressed the level of drug use for the same individuals
over time, concluding that drug use and polypharmacy
increase with increasing age, but without an increased
prevalence over time [26-30].
Secondly, some studies have applied varying time peri-
ods, different definitions of drug use and polypharmacy
or different samplings of individuals [3]. Finally, certain
studies are based on interviews, and their results might
be influenced by the sampling, recall or interview bias
impedes comparison with results from register-based
studies [15,31].
The displayed year-by-year increase in drug use, poly-
pharmacy and the mean number of dispensed drugs in
t h ep r e s e n ts t u d yi sg e n e r a l l ym i n o rc o m p a r e dt ot h e
increase shown in previous studies of the development
of drug use in the 1980 s and 1990 s, e.g. a displayed
3-fold increase in the prevalence of polypharmacy and
mean number of drugs per person during a ten year
period [2]. This difference might be explained by the
fact that our data included all individuals in the national
population. Previous studies have often used samples of
only the elderly admitted to hospitals or living in
Hovstadius et al. BMC Clinical Pharmacology 2010, 10:16
http://www.biomedcentral.com/1472-6904/10/16
Page 6 of 8nursing homes. Relatively healthy individuals might,
therefore, not have been included in these earlier stu-
dies. Another possible explanation is that the recent
efforts to reduce the increases in drug use and polyphar-
macy actually have had an effect.
Implications for clinicians and policymakers
The substantial increase in the prevalence of polyphar-
macy and excessive polypharmacy occurs simultaneously
with the introduction of new clinical guidelines aimed at
increasing the benefits of the medical treatment. The
increase also occurs when the potential risks with poly-
pharmacy have been highlighted, and various efforts
have been made to reduce the number of drugs pre-
scribed to individuals with an excessive number of
drugs, especially the elderly. In Sweden, efforts to reduce
the prevalence of polypharmacy have been focused on,
at in first hand, the reduction of unintended generic
duplication.
The assessment of the increasing prevalence of poly-
pharmacy is not interpreted in a unanimous manner.
For certain clinicians and policymakers, the results of
the present study may be interpreted as the regrettable
further development of polypharmacy, and that, in parti-
cular, excessive polypharmacy is continuing in an unde-
sirable direction. However, the results of our study may
also be interpreted to imply that a larger proportion of
patients are receiving recommended drug treatment in
line with new clinical guidelines.
T h ep r e v a l e n c eo fp o l y p h a r m a c ym a yh i d et h ef a c t
that the benefits and/or risks of polypharmacy can be
evaluated at individual level only. For clinicians, recom-
mendations are required as to the manner in which to
combine and balance different clinical guidelines to
achieve an appropriate drug therapy for patients with
multiple diseases.
Unanswered questions and future research
Over the 4-year study period, the increase in the preva-
lence of polypharmacy and excessive polypharmacy was
particularly notable for men, 12% and 20%, respectively,
and was even more notable for elderly men. This
increase in drug use remains to be analyzed, and can
possibly be associated with the introduction of new
national clinical guidelines during the period with spe-
cial relevance for men (e.g. guidelines for Heart diseases
and Prostate cancer).
Conclusions
The prevalence of polypharmacy and excessive poly-
pharmacy, as well as the mean number of dispensed
drugs per individual, increased year-by-year in Sweden
2005-2008.
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